ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells
- PMID: 17329400
- DOI: 10.1152/ajpcell.00330.2006
ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells
Abstract
System ASC amino acid transporter-2 (ASCT2) was previously demonstrated to be essential for human hepatoma cell growth and survival, as its silencing via inducible antisense RNA expression results in complete apoptosis within 48 h by a mechanism that transcends its role in amino acid delivery. To gain mechanistic insights into the reliance of cancerous liver cells on ASCT2, the aim of this study was to determine the early consequences of its silencing on the growth and survival signaling that presage apoptosis. Induced antisense ASCT2 RNA in SK-Hep1 cells led to >90% suppression of ASCT2 mRNA by 6 h and inhibition of mammalian target-of-rapamycin (mTOR)/raptor (mTOR complex-1; mTORC1) signaling by 8 h, as manifested by diminished p70 ribosomal protein S6 kinase-1 and eukaryotic initiation factor-4E (eIF4E) binding protein-1 phosphorylation, while protein synthesis rates declined by nearly 50% despite no measurable decreases in the cap binding protein eIF4G or cellular ribosomal protein content. Depressed mTORC1 signaling occurred before detectable reduction in ASCT2 activity but coincided with a 30% decline in total cellular ASCT2 protein. By 12 h after ASCT2 silencing, further decrements were observed in protein synthesis rates and ASCT2 protein and activity, each by approximately 50%, while signaling from mTOR/rictor (mTOR complex-2; mTORC2) was stimulated as indexed by enhanced phosphorylation of the Akt/PKB kinase on serine-473 and of its proapoptotic substrate Bad on serine-136. These results suggest that ASCT2 silencing inhibits mTORC1 signaling to the translational machinery followed by an mTORC2-initiated survival response, establishing a link between amino acid transporter expression and mTOR function.
Similar articles
-
Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.Int J Oncol. 2009 Oct;35(4):731-40. doi: 10.3892/ijo_00000386. Int J Oncol. 2009. PMID: 19724909
-
PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.J Biol Chem. 2007 Aug 31;282(35):25604-12. doi: 10.1074/jbc.M704343200. Epub 2007 Jun 28. J Biol Chem. 2007. PMID: 17599906
-
Receptor-recognized α₂-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells.PLoS One. 2012;7(12):e51735. doi: 10.1371/journal.pone.0051735. Epub 2012 Dec 14. PLoS One. 2012. PMID: 23272152 Free PMC article.
-
The complexes of mammalian target of rapamycin.Curr Protein Pept Sci. 2010 Sep;11(6):409-24. doi: 10.2174/138920310791824093. Curr Protein Pept Sci. 2010. PMID: 20491627 Free PMC article. Review.
-
The molecular target of rapamycin (mTOR) as a therapeutic target against cancer.Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S169-77. Cancer Biol Ther. 2003. PMID: 14508096 Review.
Cited by
-
Nutritional Stress Induced by Tryptophan-Degrading Enzymes Results in ATF4-Dependent Reprogramming of the Amino Acid Transporter Profile in Tumor Cells.Cancer Res. 2016 Nov 1;76(21):6193-6204. doi: 10.1158/0008-5472.CAN-15-3502. Epub 2016 Sep 20. Cancer Res. 2016. PMID: 27651314 Free PMC article.
-
Glutaminase - A potential target for cancer treatment.Biomedicine (Taipei). 2024 Jun 1;14(2):29-37. doi: 10.37796/2211-8039.1445. eCollection 2024. Biomedicine (Taipei). 2024. PMID: 38939098 Free PMC article. Review.
-
Homology Modeling Informs Ligand Discovery for the Glutamine Transporter ASCT2.Front Chem. 2018 Jul 24;6:279. doi: 10.3389/fchem.2018.00279. eCollection 2018. Front Chem. 2018. PMID: 30137742 Free PMC article.
-
Synthesis, Radiolabeling, and Biological Evaluation of (R)- and (S)-2-Amino-5-[(18)F]fluoro-2-methylpentanoic Acid ((R)-, (S)-[(18)F]FAMPe) as Potential Positron Emission Tomography Tracers for Brain Tumors.J Med Chem. 2015 May 14;58(9):3817-29. doi: 10.1021/jm502023y. Epub 2015 May 4. J Med Chem. 2015. PMID: 25843369 Free PMC article.
-
Enhanced glutamine utilization mediated by SLC1A5 and GPT2 is an essential metabolic feature of colorectal signet ring cell carcinoma with therapeutic potential.Ann Transl Med. 2020 Mar;8(6):302. doi: 10.21037/atm.2020.03.31. Ann Transl Med. 2020. PMID: 32355746 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous